Free Trial

Tharimmune (THAR) Competitors

Tharimmune logo
$1.75 -0.01 (-0.57%)
As of 01:24 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

THAR vs. BIVI, RVPH, CING, JATT, MTEX, QTTB, MRKR, LPCN, CARM, and PRPH

Should you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include BioVie (BIVI), Reviva Pharmaceuticals (RVPH), Cingulate (CING), JATT Acquisition (JATT), Mannatech (MTEX), Q32 Bio (QTTB), Marker Therapeutics (MRKR), Lipocine (LPCN), Carisma Therapeutics (CARM), and ProPhase Labs (PRPH). These companies are all part of the "pharmaceutical products" industry.

Tharimmune vs. Its Competitors

Tharimmune (NASDAQ:THAR) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

BioVie is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TharimmuneN/AN/A-$12.20M-$7.88-0.22
BioVieN/AN/A-$32.12M-$7.91-1.03

Tharimmune currently has a consensus target price of $17.00, suggesting a potential upside of 871.43%. Given Tharimmune's higher possible upside, equities analysts plainly believe Tharimmune is more favorable than BioVie.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tharimmune
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50
BioVie
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00

BioVie's return on equity of -100.88% beat Tharimmune's return on equity.

Company Net Margins Return on Equity Return on Assets
TharimmuneN/A -489.33% -264.34%
BioVie N/A -100.88%-78.49%

1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 10.0% of Tharimmune shares are owned by insiders. Comparatively, 2.4% of BioVie shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, BioVie had 2 more articles in the media than Tharimmune. MarketBeat recorded 2 mentions for BioVie and 0 mentions for Tharimmune. BioVie's average media sentiment score of 0.30 beat Tharimmune's score of 0.00 indicating that BioVie is being referred to more favorably in the news media.

Company Overall Sentiment
Tharimmune Neutral
BioVie Neutral

Tharimmune has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, BioVie has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.

Summary

BioVie beats Tharimmune on 7 of the 13 factors compared between the two stocks.

Get Tharimmune News Delivered to You Automatically

Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

THAR vs. The Competition

MetricTharimmuneMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.66M$2.92B$5.54B$9.00B
Dividend YieldN/A2.45%5.25%4.04%
P/E Ratio-0.2221.0327.1820.18
Price / SalesN/A293.12431.49125.05
Price / CashN/A41.1936.8257.86
Price / Book2.577.758.085.59
Net Income-$12.20M-$54.95M$3.17B$248.60M
7 Day Performance-3.85%5.68%4.13%5.18%
1 Month Performance9.37%5.09%3.80%7.11%
1 Year Performance-50.14%7.54%34.35%21.73%

Tharimmune Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
THAR
Tharimmune
2.7768 of 5 stars
$1.75
-0.6%
$17.00
+871.4%
-48.8%$4.66MN/A-0.222
BIVI
BioVie
0.6359 of 5 stars
$0.99
+5.8%
N/A+111.8%$18.29MN/A-0.1210News Coverage
RVPH
Reviva Pharmaceuticals
2.2782 of 5 stars
$0.38
+2.9%
$9.00
+2,268.4%
-69.4%$18.24MN/A-0.485
CING
Cingulate
2.7212 of 5 stars
$4.27
+3.1%
$26.00
+508.9%
+1,135.6%$18.15MN/A-0.5020News Coverage
JATT
JATT Acquisition
N/A$1.05
flat
N/A-67.7%$18.11MN/A0.003High Trading Volume
MTEX
Mannatech
0.2811 of 5 stars
$9.45
+2.9%
N/A+17.5%$17.96M$117.87M-94.50250Gap Up
QTTB
Q32 Bio
2.0313 of 5 stars
$1.46
+1.7%
$12.17
+731.1%
-92.7%$17.81M$1.16M-0.3039
MRKR
Marker Therapeutics
3.9099 of 5 stars
$1.57
+4.0%
$13.17
+738.6%
-65.6%$17.76M$6.59M-1.1860Positive News
LPCN
Lipocine
1.577 of 5 stars
$3.21
+0.5%
$9.00
+180.8%
-57.8%$17.15M$11.20M-3.1410
CARM
Carisma Therapeutics
2.3847 of 5 stars
$0.41
+0.5%
$1.93
+373.0%
-66.2%$17.05M$19.63M-0.2620Gap Down
PRPH
ProPhase Labs
0.7823 of 5 stars
$0.40
+5.0%
N/A-87.1%$16.66M$6.77M-0.32130

Related Companies and Tools


This page (NASDAQ:THAR) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners